Early Laboratory Packet Diagnosis for Successful Fighting MDS and AML (ITP and LGC)
Abstract
RNAi induce variable mutation which the prevalence is very high nowadays, ever diagnose Large Granular Chronic (LGC) patients.
Problem: High prevalence of mortality cases in ITP, MDS, and AML in which the complaint is only nausea/ vomitus, bloated, fatigue or lethargic, and progress to deadly ITP/AML we meet in everyday practice. Anemia and thrombocytopenia progress to death of ITP/AML in 2 weeks-5 months after first time hospitalized to get transfusion and dextrose 5% infusion for the used-up energy/ glycogen in the liver. The laboratory packet should support “bridge therapy” to surgery or invasive procedure, splenectomy and or chemotherapy. Method: Case report and review of my Library recommendation of Google Scholar, ChatGPT, elaborate to ScienceDirect and EBSCOHost MEDLINE full text. Recorded all the Laboratory found in the case report and references.
Result: Case Report and References of Dx/ associated with phases of ITP/MDS/AML.
Discussion: Laboratory of the symptoms in each phase ITP and MDS/AML. Conclusion: Complex biomarker vs. simple laboratory packet in early RNAi induce ITP and AML in the mapping of ITP/AML phase to fight high mortality, stay calm with right nutrition to support the body metabolism of ITP progression to AML/ MDS. High Protein Low Carbohydrate on low Albumin plasma is already built-in in all phases.
Keywords
Download Options
Introduction
Anemia and thrombocytopenia progress to dead of Immune Thrombocytopenia /Acute Myeloid Leukemia (ITP/AML) in 2 weeks-5 months after first time hospitalized to get Red Blood Cell (RBC) transfusion, and dextrose 5% infusion for the used up depleted energy/ glycogen in the liver, are often high prevalence causes of this disease in our everyday practice.1 The patients come with nausea/vomitus complaint, later, loss of appetite. Broad diagnosis and Differential Diagnosis from typhus to DHF, hepatitis, and feverish observation-hypoglycemic become high-cost, laboratory and imaging investigation, whereas clonal hematopoiesis (CH) is a common premalignant state.2 The aims of this study is to reveal the Laboratory Parsimony packet in the progress advancing hematologic malignancy in all phases to support the curing phase and tapering off. Hypothesis: Hemoglobin and platelet count lead the whole phase of chronic Myelodysplastic Syndrome (MDS)/AML, which thrombopoietin (TPO) level could playa role in classifying disease severity in AAand ITP.3 Patients with thrombocytopenia usually do not experience serious bleeding until their platelet count is very low. Previous studies have defined a new inflammatory index induce ITP, and the progression to MDS, then AML.
Conclusion
Complex biomarker vs. simple laboratory packet in early RNAi induce ITP-MDS-AML in the mapping of ITP/AML phase to fight high mortality. Stay calm with right nutrition to support the body metabolism of ITP transformation to MDS/AML.
